May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- Remote monitoring speeds recovery, lowers complications after cancer surgery
- Common supplements may heighten bleeding risk during surgery, Polish study finds
- Keeping sensory aids in place during surgery reduces delirium risk in older hip fracture patients
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
- AAAHC report spotlights top accreditation deficiencies, strategies for safer ambulatory care
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement